The study demonstrated excellent safety outcomes across all eight patients, positioning PRV211 as a promising approach to preventing cancer recurrence at the surgical site.
Innovative Approach
PRV211 is applied directly to the tumor bed following surgical resection to address microscopic cancer cells that may remain in surgical margins. The nanoengineered patch delivers localized chemotherapy when tissue barriers are removed and access is optimal.
"This study represents an important step forward in our approach to cancer surgery," said Dr. Manijeh Goldberg, PhD, Founder and CEO of Privo Technologies. "PRV211 is customized medicine that enables surgeons to deliver targeted treatment precisely where recurrence risk is highest."
Addressing Clinical Need
Post-surgical recurrence remains a significant challenge in head and neck cancer. The study enrolled patients with invasive tumors (T1 – T4) requiring surgical excision, including advanced-stage cases requiring reconstructive surgery. PRV211's targeted approach delivers chemotherapy directly to the surgical site with minimal systemic exposure.
Program Progress
PRV211 represents Arm 2 of Privo's CLN-004 clinical program. Combined with Arm 1's achievement of its primary efficacy endpoint and Arm 3's dosing initiation, the program demonstrates continued progress in localized cancer therapy development.
Next Steps
Patients will be monitored for efficacy outcomes, including loco-regional recurrence at 12 months post-surgery. A future expansion study is planned to further evaluate PRV211's potential to reduce cancer recurrence.
About Privo Technologies, Inc.
Privo Technologies is a late-stage clinical biopharmaceutical company developing localized therapies for solid tumors using its proprietary nanoengineered delivery platform, focused on improving outcomes while preserving quality of life.
For more information please visit, www.privotechnologies.com
